At the beginning of 2025, after review by the Drug Evaluation Center of the NMPA, Jiudian Pharmaceutical's dapagliflozin tablets were approved for marketing. Jiudian® dapagliflozin tablets had successfully broken through the patent barriers of the original crystal form before they were launched, and passed the consistency evaluation, ensuring the safety and effectiveness of the drug, which can reduce the medication burden for diabetic patients and improve the accessibility of diabetic patients.

According to statistics, the incidence of diabetes in my country has reached 12%, mainly type 2 diabetes. Diabetes is the disease with the most known complications. About 10 years after onset, 30%-40% of patients will have at least one complication, more than 50% of diabetic patients die of cardiovascular and cerebrovascular complications, and about 10% of diabetic patients die of kidney disease. Traditional hypoglycemic drugs cannot fully meet the growing market demand. As a "star variety" of oral hypoglycemic drugs of SGLT-2 inhibitors, dapagliflozin tablets, in addition to showing good hypoglycemic effects, have demonstrated its unique value in the treatment of adult patients with heart failure and chronic kidney disease. A large number of clinical studies have confirmed that dapagliflozin tablets can effectively lower blood sugar, reduce weight, and lower blood pressure, and have a low risk of hypoglycemia.

According to the data from Minnet, the sales of dapagliflozin tablets in China's three major terminals and six major markets exceeded 5.2 billion yuan in 2023, a year-on-year increase of 29.86%. Dapagliflozin tablets have become the "leader" in the oral diabetes chemical drug market. In the first half of 2024, its sales exceeded 3.5 billion yuan, a year-on-year increase of 39.16%. The rapid growth of the market size of dapagliflozin tablets not only verifies that dapagliflozin is widely used in clinical practice and is highly recognized by patients, but also highlights its market position in the field of diabetes treatment.

The successful approval of dapagliflozin tablets for listing not only enriches the company's product line in the field of metabolic drugs, but also opens up a broader development space for the company in the fierce market competition, and further enhances the company's competitiveness in the metabolic drug market.